News Zepbound tops Wegovy in first head-to-head weight-loss trial Eli Lilly is playing catch-up to Novo Nordisk in the fast-growing obesity therapy sector but has new data that could tip the balance in its favour.
News Abingworth 'will launch $1.5bn fund for co-developed drugs' Abingworth is reported to be raising $1.5bn for further risk-sharing, royalty-bearing development deals with large pharma groups.
News Neuralink unveils trial linking brain implant to robotic arm Neuralink has been given regulatory approval to start a new trial of its brain implant to see if it can be used to control a robotic arm
News Study finds AZ's benralizumab a 'game-changer' in asthma Researchers in the UK say that AstraZeneca's benralizumab can have a dramatic impact if it was used to treat acute asthma attacks
Digital Sponsored Putting the UK back on the map for clinical trials: NWEH par... The state of clinical trials in the UK has been a central topic of discussion for some years now, but keenly so since Brexit and following the COVID-19 pandemic.
News Amgen's big reveal of obesity data falls a little flat Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in, but don't seem to have lived up to investor expectations
News Neurocrine pays $2.9bn for Soleno and extreme hunger drug Neurocrine Biosciences has agreed a $2.9bn deal to buy Soleno Therapeutics and its treatment for a rare, genetic form of severe obesity.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.